Clinical Trials · NCT07319429
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
- Phase
- Phase 2/Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Fudan University
- Enrollment
- 260
- Start date
- Jan 2026
- Locations
- 2 sites, China
- Primary endpoint
- The complete response rate (CRR) at 32 weeks after initiating treatment.